Why did NANO.PA stock spike today?

NANO.PA stock jumped intraday on 05 Mar 2026 after new Phase 1/expansion data and renewed attention to the Janssen collaboration. Elevated volume **255074.00** and positive headlines drove short-term buying interest on EURONEXT.

What are the key risks for NANO.PA stock?

Key risks include binary clinical outcomes, tight liquidity (current ratio **0.63**), negative EPS **-1.09**, and steep valuation ratios. Partnership terms and funding rounds can materially affect the price of NANO.PA stock.

What is Meyka AI's view on NANO.PA stock?

Meyka AI rates NANO.PA **73.82/100 (B+, BUY)**. The model highlights strong momentum and upside potential but flags valuation and cash risks. This grade factors sector and benchmark comparisons, growth and analyst signals.

What price targets and forecasts exist for NANO.PA stock?

Meyka AI's forecast model projects one-year **€25.46** and three-year **€46.20**, implying **-18.40%** and **+48.08%** versus **€31.20** today. Forecasts are model-based and not guarantees.

EU Stocks

NANO.PA Nanobiotix S.A. EURONEXT up 18.41% intraday 05 Mar 2026: Momentum tied to clinical progress

ByDanny Kontos March 5, 2026March 5, 2026

Nanobiotix S.A. (NANO.PA) surged 18.41% intraday to €31.20 on 05 Mar 2026 after fresh clinical updates and heavy volume. The jump makes NANO.PA stock one of today’s top gainers on EURONEXT in Europe with 255074.00 shares traded versus average volume 158667.00. We outline the news links, key financial ratios, technicals and a Meyka AI grade and forecast to frame the move for traders and longer-term investors.